Since 1992， China has adopted a comprehensive strategy centered on universal infant hepatitis B vaccination. This approach has led to a significant reduction in the prevalence of hepatitis B surface antigen， particularly among younger age groups. Antiviral therapy not only improves the liver histology but also reduces the incidences of complications of cirrhosis and portal hypertension， as well as the risk of hepatocellular carcinoma. Clinical guidelines for the prevention and treatment of chronic hepatitis B have been periodically updated， and the prices of antiviral drugs have been substantially lowered， enhancing treatment accessibility and affordability. However， the HBV-related disease burden remains high in China due to its large population， the considerable number of individuals already chronically infected with HBV， and the low rates of diagnosis and treatment. To meet the global goal of eliminating viral hepatitis as a public health threat by 2030， large-scale testing and treatment of those already infected with HBV are critical.